Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them. By analyzing the approach, called chimeric antigen receptor (CAR) therapies, the scientists designed a “therapeutic roadmap” that identifies all current therapies as well as additional cancers that can be treated with them.

The protein adipsin, which is produced in body fat, helps protect insulin-secreting cells called pancreatic beta cells from destruction in type 2 diabetes, according to a new study by researchers at Weill Cornell Medicine and NewYork-Presbyterian. Among middle-aged adults, higher levels of the protein in the blood were also associated with protection from type 2 diabetes.

A protein that breast, lung and other cancers use to promote their spread—or metastasis—to the brain, has been identified by a team led by Weill Cornell Medicine and New York-Presbyterian investigators. The protein, CEMIP, will now be a focus of efforts to predict, prevent and treat brain metastases, which are a frequent cause of cancer deaths.

Gary George just started his third year of medical school at Weill Cornell Medicine, but he’s already constantly on the go. When not in his clinical rotation, he’s meeting up with fellow classmates before setting aside time to get work done outside the hospital. He said he was always frustrated in past years by the lack of space dedicated to study groups, student activities or even a place to just grab a quick bite to eat in between. 

Dr. Augustine M.K. Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, opened the first-ever National Conference on Medical Student Mental Health and Well-Being with a call to action.